Waldenström’s Macroglobulinemia
Beigene BGB-11417-203
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia
Trial overview
Clinical Area
Haematology
Disease / Condition
Waldenström’s Macroglobulinemia
Phase
II
GenesisCare Location(s)
Principal Investigator(s)